UBS AM
DAWN

UBS AM’s Day One Biopharmaceuticals DAWN Stock Holding History

UBS AM’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-136,991
Closed -$2.94M – 3751
2026
Q1 		$2.94M Buy
136,991
+12,569
+10% +$177K ﹤0.01% 1844
2025
Q4 		$1.16M Buy
124,422
+8,177
+7% +$68.3K ﹤0.01% 2092
2025
Q3 		$820K Sell
116,245
-59,171
-34% -$407K ﹤0.01% 2071
2025
Q2 		$1.14M Buy
175,416
+63,137
+56% +$434K ﹤0.01% 2355
2025
Q1 		$890K Buy
112,279
+36,700
+49% +$395K ﹤0.01% 2358
2024
Q4 		$958K Buy
75,579
+10,386
+16% +$145K ﹤0.01% 2380
2024
Q3 		$908K Sell
65,193
-4,537
-7% -$64.7K ﹤0.01% 2443
2024
Q2 		$961K Buy
69,730
+31,851
+84% +$466K ﹤0.01% 2386
2024
Q1 		$626K Buy
37,879
+23,579
+165% +$353K ﹤0.01% 2213
2023
Q4 		$209K Buy
+14,300
New +$173K ﹤0.01% 2485

Other funds holding DAWN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS AM's DAWN Position: Q2 2026 in Review

UBS AM sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 136,991 shares — an estimated $2.94M sold.

UBS AM first reported a position in DAWN in Q4 2023 and held it in 10 quarters. The position peaked at $2.94M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

  • UBS AM reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • UBS AM sold 136,991 Day One Biopharmaceuticals shares in Q2 2026, an estimated $2.94M.
  • UBS AM first reported a position in Day One Biopharmaceuticals in Q4 2023 and held it in 10 quarters.
  • UBS AM's Day One Biopharmaceuticals position peaked at $2.94M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.